Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8551 to 8565 of 8898 results

  1. HIV testing: increasing uptake in black Africans (PH33)

    This guidance has been updated and replaced by NICE guideline NG60.

  2. HIV testing: increasing uptake in men who have sex with men (PH34)

    This guideline has been updated and replaced by NICE guideline NG60.

  3. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

  4. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  5. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued Reference number: GID-HST10004

  6. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued Reference number: GID-DT9

  7. Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)

    Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.

  8. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

    Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.

  9. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  10. Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

    More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.

  11. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.

  12. Improving supportive and palliative care for adults with cancer (CSG4)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.